InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,185.98
(
0.10%
)
US TECH 100
17,617.60
(
0.04%
)
Dow Jones
38,881.74
(
0.08%
)
Brent Oil
83.09
(
-0.46%
)
Bitcoin
63,119.83
(
-0.07%
)
Post# of 251745
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 828
Posts 119585
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: JohnWayne post# 161161

Tuesday, 11/26/2013 8:45:58 AM

Tuesday, November 26, 2013 8:45:58 AM

Post# of 251745
Bayer offers $2.4B in cash for Algeta (AKGZF), a 27% premium to yesterday’s close:

http://finance.yahoo.com/news/bayer-makes-2-4-billion-063418187.html

Algeta has not (yet) accepted the offer.

Algeta developed the cancer radiotherapy, Xofigo and has co-marketing rights with Bayer in the US; in the rest of the world, Bayer pays Algeta a royalty on sales.

Xofigo has had a slow sales ramp since its May 2013 FDA approval, as detailed in #msg-91684833. (In the EU, Xofigo was approved by the CHMP in Sep 2013, but it is not formally cleared for marketing.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up